OTCMKTS:ALIOF ALIOF (ALIOF) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free ALIOF Stock Alerts $278.50 0.00 (0.00%) (As of 09/27/2022) Add Compare Share Share Today's Range$278.50▼$278.5050-Day Range$278.50▼$278.5052-Week Range$138.01▼$286.30VolumeN/AAverage Volume924 shsMarket Capitalization$29.89 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ALIOF alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About ALIOF Stock (OTCMKTS:ALIOF)Actelion Ltd. develops, produces and markets pharmaceutical drugs. The firm engages in research, development, manufacturing, and distribution of pharmaceutical, biological, and diagnostic products. The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann on December 30, 1999 and is headquartered in Allschwil, Switzerland.Read More ALIOF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALIOF Stock News HeadlinesAugust 24, 2023 | thestreet.com5 Things You Must Know Before the Market Opens FridayMay 5, 2023 | msn.comIndia goes Digital: 5 major indicators of MASSIVE transformationSee More Headlines Receive ALIOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALIOF and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/16/2015Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medicinals & Botanicals Sub-IndustryN/A Current SymbolOTCMKTS:ALIOF CUSIPN/A CIKN/A Webwww.actelion.com Phone(161) 565-6565Fax41-61-565-6500EmployeesN/AYear Founded1997Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares107,330,000Free FloatN/AMarket Cap$29.89 billion OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesNicholas FrancoChief Business Development Officer & EVPKey CompetitorsBiogenNASDAQ:BIIBColoplast A/SOTCMKTS:CLPBYResMedNYSE:RMDWest Pharmaceutical ServicesNYSE:WSTCardinal HealthNYSE:CAHView All Competitors Should I Buy ALIOF Stock? ALIOF Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in ALIOF: Actelion Ltd. develops, produces, and markets pharmaceutical drugs, indicating a strong presence in the healthcare industry. Vanda acquiring rights to Actelion’s multiple sclerosis drug can potentially lead to increased revenue streams for ALIOF. Recent developments in the pharmaceutical sector have shown promising growth opportunities for companies like ALIOF. ALIOF's research, development, and manufacturing capabilities position it well for future product innovations and market expansion. Considering the current stock price of ALIOF can provide insights into its valuation and potential investment returns. Cons Investors should be bearish about investing in ALIOF for these reasons: Market volatility and regulatory challenges in the pharmaceutical industry can impact ALIOF's performance. Competition from other pharmaceutical companies may pose a threat to ALIOF's market share and profitability. Global economic conditions and healthcare policies can influence the demand for pharmaceutical products, affecting ALIOF's revenue. Uncertainties surrounding future drug development and patent expirations could introduce risks to ALIOF's long-term growth prospects. Investors should carefully assess the industry trends and ALIOF's competitive positioning before making investment decisions. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these ALIOF pros and cons to contact@marketbeat.com. ALIOF Stock Analysis - Frequently Asked Questions How have ALIOF shares performed in 2024? ALIOF's stock was trading at $278.50 at the beginning of 2024. Since then, ALIOF stock has increased by 0.0% and is now trading at $278.50. View the best growth stocks for 2024 here. How were ALIOF's earnings last quarter? ALIOF (OTCMKTS:ALIOF) announced its quarterly earnings data on Monday, February, 16th. The company reported $0.87 EPS for the quarter, missing analysts' consensus estimates of $1.09 by $0.22. The firm had revenue of $501.50 million for the quarter, compared to the consensus estimate of $546.30 million. How do I buy shares of ALIOF? Shares of ALIOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ALIOF) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsMan Who Predicted 2008: “This Will be Worse.”AltimetryYou Won't Believe Who Bezos is Working With to Fight Alzheimer'sBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALIOF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.